Candidiasis: A Fungal Infection- Current Challenges and Progress in Prevention and Treatment

Author(s): Umme Hani, Hosakote G. Shivakumar, Rudra Vaghela, Riyaz Ali M. Osmani, Atul Shrivastava

Journal Name: Infectious Disorders - Drug Targets
Formerly Current Drug Targets - Infectious Disorders

Volume 15 , Issue 1 , 2015


Become EABM
Become Reviewer
Call for Editor

Abstract:

Despite therapeutic advances candidiasis remains a common fungal infection most frequently caused by C. albicans and may occur as vulvovaginal candidiasis or thrush, a mucocutaneous candidiasis. Candidiasis frequently occurs in newborns, in immune-deficient people like AIDS patients, and in people being treated with broad spectrum antibiotics. It is mainly due to C. albicans while other species such as C. tropicalis, C. glabrata, C. parapsilosis and C. krusei are increasingly isolated. OTC antifungal dosage forms such as creams and gels can be used for effective treatment of local candidiasis. Whereas, for preventing spread of the disease to deeper vital organs, candidiasis antifungal chemotherapy is preferred. Use of probiotics and development of novel vaccines is an advanced approach for the prevention of candidiasis. Present review summarizes the diagnosis, current status and challenges in the treatment and prevention of candidiasis with prime focus on host defense against candidiasis, advancements in diagnosis, probiotics role and recent progress in the development of vaccines against candidiasis.

Keywords: Antifungal agents, C. albicans, candidiasis, host defense, probiotics, vaccine.

promotion: free to download

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 15
ISSUE: 1
Year: 2015
Published on: 21 April, 2015
Page: [42 - 52]
Pages: 11
DOI: 10.2174/1871526515666150320162036

Article Metrics

PDF: 259
HTML: 44